Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2999-3005

  Maruyama, Takanori ^a   Mimura, Kousaku ^a   Izawa, Shinichiro ^a   Inoue, Ayako ^a   Shiba, Shugo ^a   Watanabe, Mitsuaki ^a   Kawaguchi, Yoshihiko ^a   Inoue, Masayuki ^a   Nogata, Hisashi ^b   Inoue, Shingo ^a   Fujii, Hideki ^a   Kono, Koji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

ADCC; Breast cancer; HER2; Herceptin; Lapatinib

Indexed keywords

ANASTROZOLE; CA 15-3 ANTIGEN; CAPECITABINE; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; NCC ST439; PROGESTERONE RECEPTOR; RITUXIMAB; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CELL SURFACE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMARY GLAND; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT FAILURE; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLOTTING, WESTERN; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GENES, ERBB-2; HUMANS; MIDDLE AGED; QUINAZOLINES; UP-REGULATION;

EID: 80051643188     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985. (Pubitemid 16169997)
2. Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Storkel S and Kiessling R: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer 87: 349-359, 2000. (Pubitemid 30451645)
3. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92: 1253-1260, 2005. (Pubitemid 40604400)
4. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G, Terracciano L and Tornillo L: HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60: 768-772, 2007. (Pubitemid 47056905)
5. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA and Ooi A: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer 98: 833-837, 2002. (Pubitemid 34286677)
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
7. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70, 1999. (Pubitemid 29411434)
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
9. Izumi Y, Xu L, di Tomaso E, Fukumura D and Jain RK: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280, 2002. (Pubitemid 34260234)
10. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA and Lipkowitz S: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900, 2001. (Pubitemid 32691907)
11. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446, 2000. (Pubitemid 30208162)
12. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H and Matsumoto Y: Impaired antibody-dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817, 2002. (Pubitemid 35204740)
13. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A and Fujii H: Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898-4904, 2005. (Pubitemid 41557210)
14. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM and Shewchuk L: A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659, 2004. (Pubitemid 39297926)
15. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J and O'Shaughnessy J: Randomized study of lapatinib alone or in combination with trastuzumab in women with ERBB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124-1130.
16. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC and Slamon DJ: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639, 2006. (Pubitemid 43259947)
17. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK and Brattain MG: Blockade of EGFR and ERBB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 66: 404-411, 2006. (Pubitemid 43166048)
18. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J and Baselga J: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28: 803-814, 2009.
19. Mimura K, Kono K, Maruyama T, Watanabe M, Izawa S, Shiba S, Mizukami Y, Kawaguchi Y, Inoue M, Kono T, Choudhury A, Kiessling R and Fujii H: Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytoxicity (ADCC) of EGFR and HER2 overexpressing esophageal cancer cell lines. Int J Cancer: 8 APR 2011, DOI: 10.1002/ijc.25896.
20. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ and Spector NL: Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26: 1066-1072, 2008.
21. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S and Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743, 2006.
22. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH and Sledge GW: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999-3005, 2008.
23. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS and Press MF: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552, 2008.
24. Ando T, Mimura K, Johansson CC, Hanson MG, Mougiakakos D, Larsson C, Martins da Palma T, Sakurai D, Norell H, Li M, Nishimura MI and Kiessling R: Transduction with the antioxidant enzyme catalase protects human T-cells against oxidative stress. J Immunol 181: 8382-8390, 2008.
25. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL and Spector NL: Combining lapatinib (GW572016), a small molecule inhibitor of ERBB1 and ERBB2 tyrosine kinases, with therapeutic anti-ERBB2 antibodies enhances apoptosis of ERBB2-overexpressing breast cancer cells. Oncogene 24: 6213-6221, 2005.